ACHIEVE LIFE SCIENCES, INC.

ACHV

$144M

Micro Cap

NASDAQIn Vitro & In Vivo Diagnostic Substances🇺🇸North AmericaSEATTLE

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

May 15, 2026

13w

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply

Market Overview

Stock performance and market intelligence

Catalyst Timeline

1 upcoming, 0 past

🎯PDUFANext

FDA PDUFA Date cytisinicline (standard)

5/15/2026

For smoking cessation. NDA filing. Extracted from SEC filing: 8-K

Source

AI Predictions & Institutional Flow

Machine learning insights and smart money movement

FDA Submissions

Pending NDA/BLA submissions with predicted PDUFA dates

Drug Pipeline

Clinical development programs and drug candidates

Drug Pipeline

Custirsen

Phase 3

Prostate Cancer

cabazitaxel

Phase 3

Prostate Cancer

Cytisinicline

Phase 3

Smoking Cessation

custirsen sodium

Phase 3

Non-small Cell Lung Cancer

OGX-427 600 mg

Phase 2

Urologic Neoplasms

TOCOSOL Paclitaxel

Phase 2

Bladder Neoplasms

TOCOSOL(R) Paclitaxel

Phase 2

Breast Cancer

S-8184 Paclitaxel Injectable Emulsion

Phase 2

Urologic Neoplasms

custirsen (OGX-011)/mitoxantrone

Phase 2

Prostate Cancer

Cytisine

Phase 2

Smoking Cessation

Drug Name	Phase	Indication	Designations
Custirsen	Phase 3	Prostate Cancer	-
cabazitaxel	Phase 3	Prostate Cancer	-
Cytisinicline	Phase 3	Smoking Cessation	-
custirsen sodium	Phase 3	Non-small Cell Lung Cancer	-
OGX-427 600 mg	Phase 2	Urologic Neoplasms	-
TOCOSOL Paclitaxel	Phase 2	Bladder Neoplasms	-
TOCOSOL(R) Paclitaxel	Phase 2	Breast Cancer	-
S-8184 Paclitaxel Injectable Emulsion	Phase 2	Urologic Neoplasms	-
custirsen (OGX-011)/mitoxantrone	Phase 2	Prostate Cancer	-
Cytisine	Phase 2	Smoking Cessation	-

Regulatory & News

Approvals, filings, and latest developments

Regulatory Approvals

ACHV News